Department of Rehabilitation Medicine, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong Province, China.
Eur Rev Med Pharmacol Sci. 2017 Oct;21(19):4431-4436.
To observe the curative effect of dl-3-n-Butylphthalide (NBP) on patients with acute cerebral infarction (ACI) and its effects on levels of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).
A total of 160 ACI patients treated in our hospital who met the criteria were selected and randomly divided into treatment group (n=80, including 42 males and 38 females) and control group (n=80, including 40 males and 40 females). The control group was treated with routine drug therapy, while the treatment group was treated with butylphthalide on this basis. The curative effect was evaluated using the National Institute of Health Stroke Scale (NIHSS) and the Activity of Daily Life Scale (ADL Scale). The levels of the two factors in serum were measured using enzyme-linked immunosorbent assay (ELISA), and the changes in the levels of the two factors in serum at different time points before and after treatment were compared between the two groups.
After treatment, the levels of the two factors in serum in both groups were significantly increased compared with those before treatment (p<0.05), and the increase in treatment group was more significant than that in control group (p<0.05). The scores of ADL scale in both groups were significantly increased after treatment compared with those before treatment, and the increase in treatment group was more significant than that in control group (p<0.05). The scores of NIHSS in both groups were significantly decreased compared with those before treatment, and the decrease in treatment group was more significant than that in control group (p<0.05).
NBP can improve the expressions of VEGF and bFGF in serum of ACI patients, and its effect is superior to that of conventional drugs.
观察 dl-3-正丁基苯酞(NBP)对急性脑梗死(ACI)患者的疗效及其对血清血管内皮生长因子(VEGF)和碱性成纤维细胞生长因子(bFGF)水平的影响。
选取我院收治的符合标准的 160 例 ACI 患者,采用随机数字表法分为治疗组(n=80,男 42 例,女 38 例)和对照组(n=80,男 40 例,女 40 例)。对照组采用常规药物治疗,治疗组在此基础上加用丁基苯酞治疗。采用美国国立卫生研究院卒中量表(NIHSS)和日常生活活动量表(ADL 量表)评估疗效。采用酶联免疫吸附试验(ELISA)检测血清中两种因子的水平,比较两组患者治疗前后不同时间点血清中两种因子水平的变化。
治疗后,两组患者血清中两种因子的水平均较治疗前明显升高(p<0.05),且治疗组升高幅度明显大于对照组(p<0.05)。治疗后两组患者 ADL 量表评分均较治疗前明显升高,且治疗组升高幅度明显大于对照组(p<0.05)。治疗后两组患者 NIHSS 评分均较治疗前明显降低,且治疗组降低幅度明显大于对照组(p<0.05)。
NBP 可提高 ACI 患者血清中 VEGF 和 bFGF 的表达,其疗效优于常规药物。